We have located links that may give you full text access.
CLINICAL TRIAL
COMPARATIVE STUDY
JOURNAL ARTICLE
RANDOMIZED CONTROLLED TRIAL
Propofol requirement for insertion of cuffed oropharyngeal airway versus laryngeal mask airway with and without fentanyl: a dose-finding study.
British Journal of Anaesthesia 2003 January
BACKGROUND: The cuffed oropharyngeal airway (COPA) is a modified Guedel-type oral airway with a cuff at its distal end. The objectives of this prospective, randomized study were to compare the COPA and the laryngeal mask airway (LMA) in terms of propofol requirement with and without fentanyl pretreatment for smooth insertions.
METHODS: Seventy-five patients undergoing general anaesthesia were randomly assigned to either a COPA (n=38) or LMA (n=37) group for airway management, and each group was further randomized to a saline-propofol or fentanyl-propofol group for anaesthesia induction. The saline-propofol group received i.v. saline and the fentanyl-propofol group received i.v. fentanyl 1 micro g kg(-1) followed 30 s later by i.v. propofol. Insertion of the device was attempted 90 s after propofol administration without the use of neuromuscular blocking agents or other adjuvants, and the responses of 'movement' or 'no movement' were judged by three observers blinded to the drug dose. Each dose of propofol at which insertion was attempted was predetermined by modification of Dixon's up-and-down method with 0.5 mg kg(-1) as the step size, and 2 mg kg(-1) as an initial dose.
RESULTS: Without fentanyl pretreatment, propofol requirement [mean (SD), 95% CI] for COPA placement [2.17 (0.38), 1.77-2.56 mg kg(-1)] was significantly less than for LMA insertion [3.42 (0.26), 3.15-3.69 mg kg(-1), P<0.001]. In contrast, propofol requirements after fentanyl were comparable between the COPA and LMA groups [1.50 (0.42), 1.06-1.94 and 1.42 (0.26), 1.15-1.69 mg kg(-1), respectively], but were less than for the placebo group with both devices (P<0.05). Haemodynamic changes and duration of apnoea were similar with both devices irrespective of fentanyl pretreatment.
CONCLUSIONS: Insertion of the COPA can be accomplished with a smaller bolus dose of propofol compared with the LMA, but propofol requirements are similar with both devices after a small dose of fentanyl.
METHODS: Seventy-five patients undergoing general anaesthesia were randomly assigned to either a COPA (n=38) or LMA (n=37) group for airway management, and each group was further randomized to a saline-propofol or fentanyl-propofol group for anaesthesia induction. The saline-propofol group received i.v. saline and the fentanyl-propofol group received i.v. fentanyl 1 micro g kg(-1) followed 30 s later by i.v. propofol. Insertion of the device was attempted 90 s after propofol administration without the use of neuromuscular blocking agents or other adjuvants, and the responses of 'movement' or 'no movement' were judged by three observers blinded to the drug dose. Each dose of propofol at which insertion was attempted was predetermined by modification of Dixon's up-and-down method with 0.5 mg kg(-1) as the step size, and 2 mg kg(-1) as an initial dose.
RESULTS: Without fentanyl pretreatment, propofol requirement [mean (SD), 95% CI] for COPA placement [2.17 (0.38), 1.77-2.56 mg kg(-1)] was significantly less than for LMA insertion [3.42 (0.26), 3.15-3.69 mg kg(-1), P<0.001]. In contrast, propofol requirements after fentanyl were comparable between the COPA and LMA groups [1.50 (0.42), 1.06-1.94 and 1.42 (0.26), 1.15-1.69 mg kg(-1), respectively], but were less than for the placebo group with both devices (P<0.05). Haemodynamic changes and duration of apnoea were similar with both devices irrespective of fentanyl pretreatment.
CONCLUSIONS: Insertion of the COPA can be accomplished with a smaller bolus dose of propofol compared with the LMA, but propofol requirements are similar with both devices after a small dose of fentanyl.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app